Rapid and Robust Continuous Purification of High-Titer Hepatitis B Virus for In Vitro and In Vivo Applications.
HBV for in vitro and in vivo assays
HBV high-titer virus stocks
heparin-affinity chromatography
hepatitis B virus
sucrose-gradient ultracentrifugation
virus purification
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
30 07 2021
30 07 2021
Historique:
received:
09
06
2021
revised:
06
07
2021
accepted:
21
07
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
3
2
2022
Statut:
epublish
Résumé
Available treatments for hepatitis B can control the virus but are rarely curative. This led to a global initiative to design new curative therapies for the 257 million patients affected. Discovery and development of these new therapies is contingent upon functional in vitro and in vivo hepatitis B virus (HBV) infection models. However, low titer and impurity of conventional HBV stocks reduce significance of in vitro infections and moreover limit challenge doses in current in vivo models. Therefore, there is a critical need for a robust, simple and reproducible protocol to generate high-purity and high-titer infectious HBV stocks. Here, we outline a three-step protocol for continuous production of high-quality HBV stocks from supernatants of HBV-replicating cell lines. This purification process takes less than 6 h, yields to high-titer stocks (up to 1 × 10
Identifiants
pubmed: 34452368
pii: v13081503
doi: 10.3390/v13081503
pmc: PMC8402639
pii:
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cell Host Microbe. 2016 Jul 13;20(1):25-35
pubmed: 27321908
Nat Commun. 2017 Jul 25;8(1):125
pubmed: 28743900
J Clin Invest. 2019 Apr 30;129(7):2932-2945
pubmed: 31039136
J Med Microbiol. 1991 Nov;35(5):291-3
pubmed: 1941999
J Virol. 2019 Sep 30;93(20):
pubmed: 31375584
J Hepatol. 2021 Jul;75(1):64-73
pubmed: 33516779
Gastroenterology. 2020 May;158(6):1762-1775.e9
pubmed: 32001321
Antimicrob Agents Chemother. 1997 Aug;41(8):1715-20
pubmed: 9257747
Hepatology. 2017 Sep;66(3):703-716
pubmed: 28195359
Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Aug;1866(8):158960
pubmed: 33932583
Life Sci Alliance. 2019 Mar 27;2(2):
pubmed: 30918010
Gastroenterology. 2016 Jan;150(1):194-205
pubmed: 26416327
Proc Natl Acad Sci U S A. 1987 Feb;84(4):1005-9
pubmed: 3029758
Viruses. 2020 Jul 30;12(8):
pubmed: 32751581
J Virol. 1998 Feb;72(2):1462-8
pubmed: 9445049
J Infect Dis. 1975 Oct;132(4):451-8
pubmed: 1185011
Methods Mol Biol. 2017;1540:15-25
pubmed: 27975304
J Virol. 2010 Nov;84(22):11994-2001
pubmed: 20719950
J Gen Virol. 2005 Mar;86(Pt 3):677-685
pubmed: 15722528
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):327-328
pubmed: 28400622
Vaccine. 2012 Mar 9;30(12):2212-9
pubmed: 22273662
Hepatology. 2001 Apr;33(4):981-8
pubmed: 11283864
J Immunol Res. 2017;2017:4828936
pubmed: 28367455
Acta Biochim Biophys Hung. 1989;24(3):245-58
pubmed: 2518621
Nat Commun. 2017 Dec 15;8(1):2146
pubmed: 29247188
Lancet. 2014 Dec 6;384(9959):2053-63
pubmed: 24954675
J Virol. 2010 Feb;84(4):1989-2000
pubmed: 20007265
Cell Microbiol. 2011 Apr;13(4):602-19
pubmed: 21129143
Vox Sang. 1981;41(2):91-7
pubmed: 7331285
Nat Commun. 2019 Jul 11;10(1):3071
pubmed: 31296856
J Hepatol. 2018 Dec;69(6):1231-1241
pubmed: 30142426
Hepatology. 2007 Dec;46(6):1759-68
pubmed: 18046710
J Clin Microbiol. 1976 Jun;3(6):626-31
pubmed: 950380
World J Gastroenterol. 2007 Jan 7;13(1):65-73
pubmed: 17206755
PLoS One. 2017 Jan 3;12(1):e0167871
pubmed: 28045894
N Engl J Med. 2004 Mar 11;350(11):1118-29
pubmed: 15014185
Antiviral Res. 2018 Mar;151:4-7
pubmed: 29309795
Hepatology. 2013 Jul;58(1):43-53
pubmed: 23292963
Virology. 2017 Sep;509:67-70
pubmed: 28605637
Viruses. 2015 Feb 10;7(2):666-79
pubmed: 25674771